🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are on the rise globally, with data suggesting more than 82 million infections each year. Particularly high rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Data and Global Access

As per data published in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an equal footing with the typical regimen, which involves a dual-drug approach. The research included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Clinicians directly involved have expressed positive views. Having a one-pill regimen of this kind is seen as a "game-changer" for gonorrhoea control. This is deemed vital to reduce the burden of the infection for people and to halt the transmission of extremely resistant gonorrhoea worldwide.